From solid tumors to metastatic carcinomas and leukemia: cancer is among the most common causes of death and has many faces. Keep reading for latest developments in early detection, staging, therapy and research.
A major new initiative aims to enable the development of advanced, specific and highly reproducible human in vitro models for greater understanding of disease and the acceleration of new medicines.
Researchers explore how ultrasound waves can be used to activate chemotherapy drugs only in targeted areas, offering a new path toward safer, more effective cancer treatment.
Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets. At the ESMO congress in Berlin, Yuting (Shelley) Liu, Head of China Business Development and Strategy of Hengrui Pharma, shared insights into how the company is translating decades of Chinese market experience into a global oncology strategy.
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, according to experts presenting at the 37th European Congress of Pathology in Vienna this September. During a session on state-of-the-art in gastrointestinal biomarkers, speakers outlined how targeted therapies and immunotherapies are transforming treatment options – but…
Underscoring the growing role of large language models (LLM) in cancer care, ESMO released the first structured set of recommendations to bring AI language models into oncology safely and effectively.
Researchers have discovered a previously unknown mechanism that explains how bacteria within a tumor can drive treatment resistance in patients with oral and colorectal cancer.
Researchers identified a targeted way to protect the brain from harmful side effects of cranial radiation therapy, potentially preserving the quality of life for millions of brain cancer survivors.
Scientists are on the way to finding a vaccine to fight off Helicobacter pylori - a bacterium found in over 60% of people - possibly preventing stomach ulcers and lowering the risk for stomach cancer.
Precision Oncology Ireland (POI), a €28M cancer research programme uniting universities, charities and industry to develop tailored diagnostic and therapeutic solutions, has now entered phase 2.
GLP-1 receptor agonists are widely prescribed for individuals with diabetes and weight loss. However, these medications may adversely affect the interpretation of cancer imaging, new research finds.
Using PET/CT imaging, researchers discovered that the biological activity of visceral fat may drive the progression of endometrial cancer, offering a novel angle for diagnosis and treatment.
Scientists have shown for the first time that glioblastoma—the deadliest form of brain cancer—affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and interferes with the body’s immune response.
Researchers from the University of Birmingham’s Bladder Cancer Research Centre have found a new way of detecting tumour DNA in urine to identify bladder cancer.
TU München researchers discover how chronic cellular stress changes gut microbiome composition, promoting cancer development through altered lipid metabolism.
Study of 3.7 million children reveals small but significant increased risk of blood cancers from medical imaging radiation, with CT scans posing highest risk
A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumours in some cancers.
Researchers explored two promising new biomarkers as potential radiotheranostic targets for endometrial cancer. This could help identify patients who are likely to respond to targeted therapeutics.
Currently, cancer treatment evaluation focuses heavily on survival outcomes, but doesn't adequately consider how treatments affect quality of life. A new policy review aims to change this.
Self-learning artificial intelligence approaches are offering a number of advantages for digital pathology when compared to established AI options. The benefits, which range from greater speed and capacitive flexibility to ‘wholly interpretable’ analyses, were outlined at the Digital Pathology and AI Congress in London.
